{"id":"artenimol","rwe":[{"pmid":"41827693","year":"2026","title":"GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41648300","year":"2026","title":"GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41216601","year":"2025","title":"Shared Biomarkers and Potential Mechanisms Between Hashimoto's Thyroiditis and Recurrent Miscarriage Revealed by Transcriptomics Analysis.","finding":"","journal":"International journal of general medicine","studyType":"Clinical Study"},{"pmid":"40840184","year":"2026","title":"Differentially expressed proteins in the prefrontal cortex of individuals with alcohol use disorder: a multi-level biological network analysis.","finding":"","journal":"Computational biology and chemistry","studyType":"Clinical Study"},{"pmid":"40339110","year":"2025","title":"Genomic Correlations, Shared Loci, and Drug Targets Between Polycystic Ovary Syndrome and Asthma: Insights From Genome-wide Association Analysis.","finding":"","journal":"The Journal of clinical endocrinology and metabolism","studyType":"Clinical Study"}],"tags":[{"label":"artenimol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P01BE05","category":"atc"},{"label":"Active","category":"status"},{"label":"Malaria","category":"indication"},{"label":"Sigma-Tau Industrie Farmaceutiche Riunite S.p.A","category":"company"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Sigma-Tau Industrie Farmaceutiche Riunite S.p.A","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ARTENIMOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:16:01.235012+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:16:06.442342+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:16:01.302722+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTENIMOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:16:06.763846+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Ferriprotoporphyrin IX binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:07.860112+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL307261/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:07.520024+00:00"}},"allNames":"alaxin","offLabel":[],"synonyms":["dihydroartemisinin","dihydroartemisinine","dihydroqinghaosu","alaxin","cotecxin","cotexin","beta-Dihydroartemisinin","artenimol"],"timeline":[{"date":"2011-10-27","type":"positive","source":"DrugCentral","milestone":"EMA approval (Sigma-Tau Industrie Farmaceutiche Riunite S.p.A)"}],"brandName":"Alaxin","ecosystem":[{"indication":"Malaria","otherDrugs":[{"name":"pyrimethamine","slug":"pyrimethamine","company":"Amedra Pharms"},{"name":"quinidine","slug":"quinidine","company":"Lilly"},{"name":"tafenoquine","slug":"tafenoquine","company":"Glaxosmithkline"}],"globalPrevalence":240000}],"mechanism":{"modality":"Small Molecule","drugClass":"artenimol","explanation":"","oneSentence":"","technicalDetail":"Alaxin is a small molecule that targets the Plasmodium parasite's metabolic pathways, specifically inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), which is essential for the parasite's survival and replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4194","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ARTENIMOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTENIMOL","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:49:53.500629","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:09.060497+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"artemether","drugSlug":"artemether","fdaApproval":"2009-04-07","relationship":"same-class"},{"drugName":"artesunate","drugSlug":"artesunate","fdaApproval":"2020-05-26","patentExpiry":"Feb 16, 2044","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"artenimol","indications":{"approved":[{"name":"Malaria","source":"DrugCentral","snomedId":61462000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"artemether","brandName":"artemether","genericName":"artemether","approvalYear":"2009","relationship":"same-class"},{"drugId":"artesunate","brandName":"artesunate","genericName":"artesunate","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06075264","phase":"PHASE2","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-12-06","conditions":["Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia"],"enrollment":27,"completionDate":"2027-12"},{"nctId":"NCT07007078","phase":"EARLY_PHASE1","title":"Efficacy of Dihydroartemisinin for Treating Acne Vulgaris","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-06","conditions":["Acne Vulgaris"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT05555862","phase":"PHASE2","title":"Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-02-10","conditions":["Anal High Grade Squamous Intraepithelial Lesion","Anal Precancerous Condition","AIN 2/3","HPV Infection","Anal Dysplasia","HPV Disease"],"enrollment":17,"completionDate":"2026-12-31"},{"nctId":"NCT06206564","phase":"PHASE2","title":"Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2024-01-12","conditions":["Anal High-grade Squamous Intraepithelial Lesion","Anal HSIL","Anal HPV Infection","AIN"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT06516042","phase":"PHASE3","title":"Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"PATH","startDate":"2024-08-21","conditions":["Plasmodium Falciparum","Malaria"],"enrollment":10350,"completionDate":"2025-07"},{"nctId":"NCT06417099","phase":"PHASE2","title":"Efficacy of Dihydroartemisinin for Treating PCOS","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-24","conditions":["Polycystic Ovary Syndrome"],"enrollment":30,"completionDate":"2025-03-30"},{"nctId":"NCT06842524","phase":"PHASE2","title":"Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-04-16","conditions":["Polycystic Ovary Syndrome (PCOS)"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT05465135","phase":"PHASE4","title":"The Effect of Dihydroartemisinin in PCOS","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-07-01","conditions":["Polycystic Ovary Syndrome"],"enrollment":19,"completionDate":"2023-04-23"},{"nctId":"NCT05946642","phase":"PHASE3","title":"Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2023-07-15","conditions":["Malaria"],"enrollment":13000,"completionDate":"2024-12-31"},{"nctId":"NCT06036030","phase":"PHASE2","title":"Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua","status":"COMPLETED","sponsor":"Syamsudin Abdillah,Ph.D, Pharm D","startDate":"2019-01-11","conditions":["Malaria,Falciparum","Malaria, Vivax","Malaria","Infections","Uncomplicated Malaria","Uncomplicated Plasmodium Falciparum"],"enrollment":50,"completionDate":"2019-04-16"},{"nctId":"NCT05829187","phase":"PHASE2","title":"Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency","status":"COMPLETED","sponsor":"Syamsudin Abdillah,Ph.D, Pharm D","startDate":"2022-11-01","conditions":["Uncomplicated Plasmodium Falciparum"],"enrollment":36,"completionDate":"2022-12-31"},{"nctId":"NCT04609098","phase":"PHASE2","title":"Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-10-29","conditions":["Malaria, Falciparum"],"enrollment":80,"completionDate":"2020-12-23"},{"nctId":"NCT04049916","phase":"PHASE2,PHASE3","title":"Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-12","conditions":["Malaria,Falciparum"],"enrollment":100,"completionDate":"2020-01-07"},{"nctId":"NCT02110784","phase":"PHASE2","title":"Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2014-06-18","conditions":["Malaria, Vivax"],"enrollment":27,"completionDate":"2017-04-30"},{"nctId":"NCT00682578","phase":"PHASE3","title":"A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-07","conditions":["Uncomplicated Falciparum Malaria","Vivax Malaria"],"enrollment":1086,"completionDate":"2010-02"},{"nctId":"NCT01930331","phase":"PHASE4","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO","status":"COMPLETED","sponsor":"Ifakara Health Institute","startDate":"2014-01-07","conditions":["Plasmodium Falciparum","Malaria, Falciparum"],"enrollment":60,"completionDate":"2015-06-01"},{"nctId":"NCT03396393","phase":"PHASE2","title":"Exploratory Study of DHA in Systemic Lupus Erythematosus Patients","status":"UNKNOWN","sponsor":"Kunming Pharmaceuticals, Inc.","startDate":"2018-03","conditions":["Systemic Lupus Erythematosus"],"enrollment":120,"completionDate":"2022-12"},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":["Malaria, Vivax"],"enrollment":120,"completionDate":"2015-04-08"},{"nctId":"NCT01992900","phase":"PHASE2","title":"A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2013-11","conditions":["Malaria,Falciparum"],"enrollment":300,"completionDate":"2016-01"},{"nctId":"NCT01887821","phase":"PHASE4","title":"Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2013-02","conditions":["Plasmodium Vivax Malaria"],"enrollment":330,"completionDate":"2015-06"},{"nctId":"NCT02199951","phase":"","title":"Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania","status":"UNKNOWN","sponsor":"INDEPTH Network","startDate":"2013-09","conditions":["Malaria"],"enrollment":10000,"completionDate":"2014-12"},{"nctId":"NCT01288820","phase":"PHASE3","title":"Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-01","conditions":["Vivax Malaria"],"enrollment":331,"completionDate":"2012-04"},{"nctId":"NCT01103830","phase":"PHASE1","title":"Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2010-02","conditions":["Malaria, Falciparum"],"enrollment":287,"completionDate":"2010-12"},{"nctId":"NCT00529620","phase":"PHASE3","title":"Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2007-09","conditions":["Malaria"],"enrollment":1833,"completionDate":"2007-12"}],"_emaApprovals":[{"date":"2011-10-27","status":"Authorised","company":"Sigma-Tau Industrie Farmaceutiche Riunite S.p.A"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"014244","UNII":"6A9O50735X","CHEBI":"CHEBI:135921","INN_ID":"7777","UMLSCUI":"C2828299","chemblId":"CHEMBL307261","ChEMBL_ID":"CHEMBL252518","KEGG_DRUG":"D07362","DRUGBANK_ID":"DB11638","PUBCHEM_CID":"3000518","SNOMEDCT_US":"713474002","IUPHAR_LIGAND_ID":"9957","MESH_SUPPLEMENTAL_RECORD_UI":"C039060"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Sigma-Tau Industrie Farmaceutiche Riunite S.p.A","relationship":"Current Owner"}],"publicationCount":33,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BE05","allCodes":["P01BE05","P01BF05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 26","pmid":"41827693","title":"GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","journal":"Cancers"},{"date":"2026 Jan 16","pmid":"41648300","title":"GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","journal":"bioRxiv : the preprint server for biology"},{"date":"2025","pmid":"41216601","title":"Shared Biomarkers and Potential Mechanisms Between Hashimoto's Thyroiditis and Recurrent Miscarriage Revealed by Transcriptomics Analysis.","journal":"International journal of general medicine"},{"date":"2026 Feb","pmid":"40840184","title":"Differentially expressed proteins in the prefrontal cortex of individuals with alcohol use disorder: a multi-level biological network analysis.","journal":"Computational biology and chemistry"},{"date":"2025 Aug 7","pmid":"40339110","title":"Genomic Correlations, Shared Loci, and Drug Targets Between Polycystic Ovary Syndrome and Asthma: Insights From Genome-wide Association Analysis.","journal":"The Journal of clinical endocrinology and metabolism"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Sigma-Tau Industrie Farmaceutiche Riunite S.p.A","companyId":"sigma-tau-industrie-farmaceutiche-riunite-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:09.060497+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}